文献速递消化道肿瘤与早癌消化内镜

path_MMR携带者75岁前按基因与性别的癌症风险及生存:前瞻性Lynch综合征数据库报告

Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database.
PubMed 文献 · Gut · 2017-07-28

这项观察性国际多中心研究前瞻性随访3119例path_MMR携带者共24475人年,报告75岁累积癌症发病率和5年生存率。path_MLH1、path_MSH2和path_MSH6携带者结直肠癌风险分别为46%、43%和15%,子宫内膜癌为43%、57%和46%,不同基因型风险谱不同。path_PMS2携带者癌症风险较低,作者认为风险咨询和监测治疗计划应按年龄、性别和path_MMR变异个体化定制。

要点

  • path_MLH1、path_MSH2、path_MSH6携带者75岁结直肠癌累积风险分别为46%、43%、15%。
  • path_MLH1、path_MSH2、path_MSH6携带者75岁子宫内膜癌风险分别为43%、57%、46%。
  • path_PMS2携带者癌症风险较低,风险估算应按年龄、性别和path_MMR变异定制。

核心结论

  • 不同path_MMR变异携带者随年龄增长呈现不同的癌症风险和生存模式。
  • 用于咨询及监测和治疗计划的风险估算应按每例患者的年龄、性别和path_MMR变异定制。
  • 研究团队已更新开放获取网站www.lscarisk.org以方便上述应用。

研究设计与样本

  • 观察性、国际性、多中心研究,旨在确定path_MMR携带者75岁前前瞻性观察到的癌症发生率和生存。
  • 共随访3119例患者,总随访24475人年。

主要发现

  • path_MLH1、path_MSH2、path_MSH6携带者75岁结直肠癌累积发病率分别为46%、43%、15%。
  • path_MLH1、path_MSH2、path_MSH6携带者75岁子宫内膜癌累积发病率分别为43%、57%、46%,卵巢癌分别为10%、17%、13%。
  • path_MLH1、path_MSH2、path_MSH6携带者75岁上消化道(胃、十二指肠、胆管或胰腺)癌累积发病率分别为21%、10%、7%,泌尿道癌分别为8%、25%、11%,前列腺癌分别为17%、32%、18%,脑肿瘤分别为1%、5%、1%。
  • 卵巢癌主要发生于绝经前,而上消化道、泌尿道和前列腺癌主要发生于较大年龄。
  • 前列腺癌总体5年生存率为100%,膀胱为93%,输尿管为85%,十二指肠为67%,胃为61%,胆管为29%,脑为22%,胰腺为0%;path_PMS2携带者癌症风险较低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most patients with path_MMR gene variants (Lynch syndrome (LS)) now survive both their first and subsequent cancers, resulting in a growing number of older patients with LS for whom limited information exists with respect to cancer risk and survival. OBJECTIVE AND DESIGN: This observational, international, multicentre study aimed to determine prospectively observed incidences of cancers and survival in path_MMR carriers up to 75 years of age. RESULTS: 3119 patients were followed for a total of 24 475 years. Cumulative incidences at 75 years (risks) for colorectal cancer were 46%, 43% and 15% in path_MLH1, path_MSH2 and path_MSH6 carriers; for endometrial cancer 43%, 57% and 46%; for ovarian cancer 10%, 17% and 13%; for upper gastrointestinal (gastric, duodenal, bile duct or pancreatic) cancers 21%, 10% and 7%; for urinary tract cancers 8%, 25% and 11%; for prostate cancer 17%, 32% and 18%; and for brain tumours 1%, 5% and 1%, respectively. Ovarian cancer occurred mainly premenopausally. By contrast, upper gastrointestinal, urinary tract and prostate cancers occurred predominantly at older ages. Overall 5-year survival for prostate cancer was 100%, urinary bladder 93%, ureter 85%, duodenum 67%, stomach 61%, bile duct 29%, brain 22% and pancreas 0%. Path_PMS2 carriers had lower risk for cancer. CONCLUSION: Carriers of different path_MMR variants exhibit distinct patterns of cancer risk and survival as they age. Risk estimates for counselling and planning of surveillance and treatment should be tailored to each patient's age, gender and path_MMR variant. We have updated our open-access website www.lscarisk.org to facilitate this.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Møller P, Seppälä TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 2017. PMID: 28754778. doi:10.1136/gutjnl-2017-314057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。